You are here

Article Text

Article menu
Download PDFPDF
Correspondence
To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic
  1. Konstantinos Parperis1,2
  1. 1 Internal Medicine, Division of Rheumatology, University of Cyprus Medical School, Nicosia, Cyprus
  2. 2 Medicine, Division of Rheumatology, University of Arizona College of Medicine, Phoenix, Arizona, USA
  1. Correspondence to Dr Konstantinos Parperis, Internal Medicine, Division of Rheumatology, University of Cyprus Medical School, Nicosia 1678, Cyprus; kparpe02{at}ucy.ac.cy

https://doi.org/10.1136/annrheumdis-2020-217557

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the letter by Spinelli et al published in the Annals of the Rheumatic Diseases.1 The authors describe the existing scientific evidence concerning the potential antiviral activity of chloroquine and hydroxychloroquine (HCQ) against SARS-CoV-2 (COVID-19) infection in vitro, and the available clinical studies.

    In my opinion, caution must be exercised before drawing any conclusions about the efficacy of antimalarials as prophylactic or therapeutic options for COVID-19 infection, given the concerns raised by healthcare providers related to inadequate supply for patients with chronic conditions such as systemic lupus erythematosus and rheumatoid arthritis.2 …

    View Full Text

    Footnotes

    • Contributors KP: conception or design of the work, acquisition, analysis or interpretation of data for the work, drafting the work or revising it critically for important intellectual content, final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles